Drugs that contain Naloxone Hydrochloride
1. Evzio patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8313466 | KALEO INC | Devices, systems and methods for medicament delivery |
Nov, 2024
(11 months from now) | |
| US8425462 | KALEO INC | Devices, systems, and methods for medicament delivery |
Nov, 2024
(11 months from now) | |
| US7918823 | KALEO INC | Devices, systems and methods for medicament delivery |
Nov, 2024
(11 months from now) | |
| US8608698 | KALEO INC | Devices, systems and methods for medicament delivery |
Nov, 2024
(11 months from now) | |
| US8361029 | KALEO INC | Devices, systems and methods for medicament delivery |
Nov, 2024
(11 months from now) | |
| US9056170 | KALEO INC | Devices, systems and methods for medicament delivery |
Nov, 2024
(11 months from now) | |
| US10314977 | KALEO INC | Devices, systems and methods for medicament delivery |
Nov, 2024
(11 months from now) | |
| US10737028 | KALEO INC | Devices, systems and methods for medicament delivery |
Nov, 2024
(11 months from now) | |
| US9737669 | KALEO INC | Devices, systems and methods for medicament delivery |
Nov, 2024
(11 months from now) | |
| US7731690 | KALEO INC | Devices, systems and methods for medicament delivery |
Jan, 2025
(1 year, 1 month from now) | |
| US8016788 | KALEO INC | Devices, systems and methods for medicament delivery |
Mar, 2025
(1 year, 3 months from now) | |
| US10335549 | KALEO INC | Devices, systems and methods for medicament delivery |
Apr, 2025
(1 year, 4 months from now) | |
| US9278182 | KALEO INC | Devices, systems and methods for medicament delivery |
Feb, 2026
(2 years from now) | |
| US8926594 | KALEO INC | Devices, systems and methods for medicament delivery |
Mar, 2026
(2 years from now) | |
| US7731686 | KALEO INC | Devices, systems and methods for medicament delivery |
Jun, 2026
(2 years from now) | |
| US10960155 | KALEO INC | Devices, systems and methods for medicament delivery |
Jun, 2026
(2 years from now) | |
| US11590286 | KALEO INC | Devices, systems and methods for medicament delivery |
Dec, 2026
(3 years from now) | |
| US9238108 | KALEO INC | Medicament delivery device having an electronic circuit system |
Feb, 2027
(3 years from now) | |
| US8206360 | KALEO INC | Devices, systems and methods for medicament delivery |
Feb, 2027
(3 years from now) | |
| US9724471 | KALEO INC | Devices, systems, and methods for medicament delivery |
May, 2027
(3 years from now) | |
| US7947017 | KALEO INC | Devices, systems and methods for medicament delivery |
Mar, 2028
(4 years from now) | |
| US7749194 | KALEO INC | Devices, systems, and methods for medicament delivery |
Oct, 2028
(4 years from now) | |
| US8231573 | KALEO INC | Medicament delivery device having an electronic circuit system |
Nov, 2028
(4 years from now) | |
| US8226610 | KALEO INC | Medical injector with compliance tracking and monitoring |
Apr, 2029
(5 years from now) | |
| US8021344 | KALEO INC | Medicament delivery device configured to produce an audible output |
Nov, 2029
(5 years from now) | |
| US9474869 | KALEO INC | Medicament delivery device for administration of opioid antagonists including formulations for naloxone |
Feb, 2031
(7 years from now) | |
| US8939943 | KALEO INC | Medicament delivery device for administration of opioid antagonists including formulations for naloxone |
Feb, 2031
(7 years from now) | |
| US10322239 | KALEO INC | Medicament delivery device for administration of opioid antagonists including formulations for naloxone |
Feb, 2031
(7 years from now) | |
| US9022022 | KALEO INC | Medicament delivery device for administration of opioid antagonists including formulations for naloxone |
Feb, 2031
(7 years from now) | |
| US10143972 | KALEO INC | Ultrafiltration membrane and a preparation method thereof |
May, 2031
(7 years from now) | |
| US8627816 | KALEO INC | Medicament delivery device for administration of opioid antagonists including formulations for naloxone |
Feb, 2032
(8 years from now) | |
| US9517307 | KALEO INC | Devices and methods for delivering opioid antagonists including formulations for naloxone |
Jul, 2034
(10 years from now) | |
| US10220158 | KALEO INC | Devices and methods for delivering opioid antagonists including formulations for naloxone |
Mar, 2035
(11 years from now) | |
Market Authorisation Date: 03 April, 2014
Treatment: Method for confirming dose delivery; Use of a delivery device to administer a dose of naloxone; Use of a delivery device to deliver a dose of naloxone; Use of an auto injector to administer naloxone h...
Dosage: SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS
EVZIO family patents
2. Evzio (autoinjector) patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8425462 | KALEO INC | Devices, systems, and methods for medicament delivery |
Nov, 2024
(11 months from now) | |
| US8608698 | KALEO INC | Devices, systems and methods for medicament delivery |
Nov, 2024
(11 months from now) | |
| US8313466 | KALEO INC | Devices, systems and methods for medicament delivery |
Nov, 2024
(11 months from now) | |
| US9737669 | KALEO INC | Devices, systems and methods for medicament delivery |
Nov, 2024
(11 months from now) | |
| US10314977 | KALEO INC | Devices, systems and methods for medicament delivery |
Nov, 2024
(11 months from now) | |
| US10737028 | KALEO INC | Devices, systems and methods for medicament delivery |
Nov, 2024
(11 months from now) | |
| US7918823 | KALEO INC | Devices, systems and methods for medicament delivery |
Nov, 2024
(11 months from now) | |
| US8361029 | KALEO INC | Devices, systems and methods for medicament delivery |
Nov, 2024
(11 months from now) | |
| US9056170 | KALEO INC | Devices, systems and methods for medicament delivery |
Nov, 2024
(11 months from now) | |
| US7731690 | KALEO INC | Devices, systems and methods for medicament delivery |
Jan, 2025
(1 year, 1 month from now) | |
| US8016788 | KALEO INC | Devices, systems and methods for medicament delivery |
Mar, 2025
(1 year, 3 months from now) | |
| US10335549 | KALEO INC | Devices, systems and methods for medicament delivery |
Apr, 2025
(1 year, 4 months from now) | |
| US9278182 | KALEO INC | Devices, systems and methods for medicament delivery |
Feb, 2026
(2 years from now) | |
| US8926594 | KALEO INC | Devices, systems and methods for medicament delivery |
Mar, 2026
(2 years from now) | |
| US7731686 | KALEO INC | Devices, systems and methods for medicament delivery |
Jun, 2026
(2 years from now) | |
| US10960155 | KALEO INC | Devices, systems and methods for medicament delivery |
Jun, 2026
(2 years from now) | |
| US11590286 | KALEO INC | Devices, systems and methods for medicament delivery |
Dec, 2026
(3 years from now) | |
| US9238108 | KALEO INC | Medicament delivery device having an electronic circuit system |
Feb, 2027
(3 years from now) | |
| US8206360 | KALEO INC | Devices, systems and methods for medicament delivery |
Feb, 2027
(3 years from now) | |
| US9724471 | KALEO INC | Devices, systems, and methods for medicament delivery |
May, 2027
(3 years from now) | |
| US7947017 | KALEO INC | Devices, systems and methods for medicament delivery |
Mar, 2028
(4 years from now) | |
| US7749194 | KALEO INC | Devices, systems, and methods for medicament delivery |
Oct, 2028
(4 years from now) | |
| US8231573 | KALEO INC | Medicament delivery device having an electronic circuit system |
Nov, 2028
(4 years from now) | |
| US8226610 | KALEO INC | Medical injector with compliance tracking and monitoring |
Apr, 2029
(5 years from now) | |
| US8021344 | KALEO INC | Medicament delivery device configured to produce an audible output |
Nov, 2029
(5 years from now) | |
| US9474869 | KALEO INC | Medicament delivery device for administration of opioid antagonists including formulations for naloxone |
Feb, 2031
(7 years from now) | |
| US10322239 | KALEO INC | Medicament delivery device for administration of opioid antagonists including formulations for naloxone |
Feb, 2031
(7 years from now) | |
| US9022022 | KALEO INC | Medicament delivery device for administration of opioid antagonists including formulations for naloxone |
Feb, 2031
(7 years from now) | |
| US8939943 | KALEO INC | Medicament delivery device for administration of opioid antagonists including formulations for naloxone |
Feb, 2031
(7 years from now) | |
| US10143792 | KALEO INC | Medicament delivery device for administration of opioid antagonists including formulations for naloxone |
May, 2031
(7 years from now) | |
| US8627816 | KALEO INC | Medicament delivery device for administration of opioid antagonists including formulations for naloxone |
Feb, 2032
(8 years from now) | |
| US9517307 | KALEO INC | Devices and methods for delivering opioid antagonists including formulations for naloxone |
Jul, 2034
(10 years from now) | |
| US10220158 | KALEO INC | Devices and methods for delivering opioid antagonists including formulations for naloxone |
Mar, 2035
(11 years from now) | |
Market Authorisation Date: 19 October, 2016
Treatment: Method for confirming dose delivery; Use of a delivery device to administer a dose of naloxone; Use of a delivery device to deliver a dose of naloxone; Use of an auto injector to administer naloxone h...
Dosage: SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS
EVZIO (AUTOINJECTOR) family patents
3. Kloxxado patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11628139 | HIKMA | Liquid naloxone spray |
Aug, 2034
(10 years from now) | |
| US11617713 | HIKMA | Liquid naloxone spray |
Aug, 2034
(10 years from now) | |
| US10973814 | HIKMA | Liquid naloxone spray |
Aug, 2034
(10 years from now) | |
| US10722510 | HIKMA | Liquid naloxone spray |
Aug, 2034
(10 years from now) | |
| US11135155 | HIKMA | Liquid naloxone spray |
Aug, 2034
(10 years from now) | |
Market Authorisation Date: 29 April, 2021
Treatment: Use of naloxone for the emergency treatment of known or suspected opioid overdose, as manifested by respiratory and/or central nervous system depression, for adult and pediatric patients
Dosage: SPRAY;NASAL
KLOXXADO family patents
4. Naloxone Hydrochloride (autoinjector) patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10314977 | KALEO INC | Devices, systems and methods for medicament delivery |
Nov, 2024
(11 months from now) | |
| US9737669 | KALEO INC | Devices, systems and methods for medicament delivery |
Nov, 2024
(11 months from now) | |
| US9056170 | KALEO INC | Devices, systems and methods for medicament delivery |
Nov, 2024
(11 months from now) | |
| US8608698 | KALEO INC | Devices, systems and methods for medicament delivery |
Nov, 2024
(11 months from now) | |
| US7918823 | KALEO INC | Devices, systems and methods for medicament delivery |
Nov, 2024
(11 months from now) | |
| US10737028 | KALEO INC | Devices, systems and methods for medicament delivery |
Nov, 2024
(11 months from now) | |
| US8361029 | KALEO INC | Devices, systems and methods for medicament delivery |
Nov, 2024
(11 months from now) | |
| US8425462 | KALEO INC | Devices, systems, and methods for medicament delivery |
Nov, 2024
(11 months from now) | |
| US8313466 | KALEO INC | Devices, systems and methods for medicament delivery |
Nov, 2024
(11 months from now) | |
| US7731690 | KALEO INC | Devices, systems and methods for medicament delivery |
Jan, 2025
(1 year, 1 month from now) | |
| US8016788 | KALEO INC | Devices, systems and methods for medicament delivery |
Mar, 2025
(1 year, 3 months from now) | |
| US10335549 | KALEO INC | Devices, systems and methods for medicament delivery |
Apr, 2025
(1 year, 4 months from now) | |
| US11590286 | KALEO INC | Devices, systems and methods for medicament delivery |
Dec, 2026
(3 years from now) | |
| US7947017 | KALEO INC | Devices, systems and methods for medicament delivery |
Mar, 2028
(4 years from now) | |
| US10322239 | KALEO INC | Medicament delivery device for administration of opioid antagonists including formulations for naloxone |
Feb, 2031
(7 years from now) | |
| US9474869 | KALEO INC | Medicament delivery device for administration of opioid antagonists including formulations for naloxone |
Feb, 2031
(7 years from now) | |
| US9814838 | KALEO INC | Medicament delivery device for administration of opioid antagonists including formulations for naloxone |
Feb, 2031
(7 years from now) | |
| US8939943 | KALEO INC | Medicament delivery device for administration of opioid antagonists including formulations for naloxone |
Feb, 2031
(7 years from now) | |
| US9022022 | KALEO INC | Medicament delivery device for administration of opioid antagonists including formulations for naloxone |
Feb, 2031
(7 years from now) | |
| US10143792 | KALEO INC | Medicament delivery device for administration of opioid antagonists including formulations for naloxone |
May, 2031
(7 years from now) | |
Market Authorisation Date: 28 February, 2022
Treatment: Use of a delivery device to administer a dose of naloxone; Use of a delivery device to deliver a dose of naloxone
Dosage: SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS
NALOXONE HYDROCHLORIDE (AUTOINJECTOR) family patents
5. Narcan patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9775838 | EMERGENT | Nasal drug products and methods of their use |
Mar, 2035
(11 years from now) | |
| US9629965 | EMERGENT | Nasal drug products and methods of their use |
Mar, 2035
(11 years from now) | |
| US10085937 | EMERGENT | Nasal drug products and methods of their use |
Mar, 2035
(11 years from now) | |
| US9480644 | EMERGENT | Nasal drug products and methods of their use |
Mar, 2035
(11 years from now) | |
| US9561177 | EMERGENT | Nasal drug products and methods of their use |
Mar, 2035
(11 years from now) | |
| US9707226 | EMERGENT | Nasal drug products and methods of their use |
Mar, 2035
(11 years from now) | |
| US9468747 | EMERGENT | Nasal drug products and methods of their use |
Mar, 2035
(11 years from now) | |
| US9211253 | EMERGENT | Nasal drug products and methods of their use |
Mar, 2035
(11 years from now) | |
Market Authorisation Date: 18 November, 2015
Treatment: Use of naloxone hydrochloride for emergency treatment of known or suspected opioid overdose, as manifested by respiratory and/or central nervous system depression.
Dosage: SPRAY, METERED;NASAL
NARCAN family patents
6. Rivive patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11020343 | HARM REDUCTION THERP | Intranasal pharmaceutical dosage forms comprising naloxone |
May, 2032
(8 years from now) | |
Market Authorisation Date: 28 July, 2023
Treatment: Use of intranasal naloxone for the treatment of opioid overdose
Dosage: SPRAY, METERED;NASAL
RIVIVE family patents
7. Zimhi patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11027072 | ADAMIS PHARMS CORP | Emergency devices |
May, 2039
(15 years from now) | |
| US11571518 | ADAMIS PHARMS CORP | NA |
Jun, 2041
(17 years from now) | |
Market Authorisation Date: 15 October, 2021
Treatment: A method for administering a therapeutic dose of an opioid antagonist comprising an emergency syringe device; A method for administering a therapeutic dose of an opioid antagonist comprising an emerge...
Dosage: SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS
ZIMHI family patents